Quantcast
Home > Quotes > HTBX
HTBX

Heat Biologics, Inc. Common Stock (HTBX) Quote & Summary Data

$1.28
*  
0.06
4.48%
Get HTBX Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading HTBX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6.5
Today's High / Low
$ 1.3518 / $ 1.26
Share Volume
126,774
50 Day Avg. Daily Volume
276,774
Previous Close
$ 1.34
52 Week High / Low
$ 4.50 / $ 1.09
Market Cap
41,545,144
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.09

Intraday Chart

Shares Traded

Share Volume:
126,774
50 Day Avg. Daily Volume:
276,774

Trading Range

The current last sale of $1.28 is 17.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.3518 $ 4.50
 Low: $ 1.26 $ 1.09

Company Description (as filed with the SEC)

We are a biopharmaceutical company developing approaches to activate and co-stimulate a patient's immune system against cancer. Our co-stimulatory antibody is designed to harness the body's natural antigen specific immune activation and tolerance mechanisms to reprogram the immunity and provide a long-term, durable clinical effect. Our T-cell activating platform (TCAP) produces therapies designed to turn immunologically "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Unlike many other "patient specific" immunotherapy approaches, our drugs are "off-the-shelf" which means that we can administer drug immediately without extracting patient material at a substantially lower cost of goods sold. Our TCAP product candidates from our ImPACT® and ComPACT(TM) platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.  ... More ...  


Risk Grade

Where does HTBX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.35
Open Date:
Dec. 13, 2018
Close Price:
$ 1.28
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info